003520.KS
Yungjin Pharm. Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 1,112.00
−0.98%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 253.0B | 254.3B | 252.0B | 234.9B | 218.4B |
| Cost of Revenue | 179.7B | 178.4B | 171.7B | 162.8B | 153.6B |
| Gross Profit | 73.3B | 75.9B | 80.3B | 72.6B | 64.7B |
| Operating Expenses | |||||
| R&D Expense | 8.5B | 10.3B | 12.7B | 13.6B | 14.4B |
| SG&A Expense | 24.0B | 29.7B | 27.1B | 24.0B | 22.4B |
| General & Admin Expense | 1.7B | 2.4B | 2.5B | 2.4B | 2.7B |
| Selling & Marketing Expense | 22.2B | 27.3B | 24.6B | 21.6B | 19.7B |
| Other Expenses | 47.7B | 32.4B | 31.9B | 31.9B | 35.3B |
| Total Operating Expenses | 77.6B | 72.4B | 71.6B | 69.5B | 72.1B |
| Cost and Expenses | 257.3B | 250.8B | 243.3B | 231.8B | 225.7B |
| Operating Income (EBIT) | (4.3B) | 3.4B | 8.7B | 3.1B | (7.4B) |
| Non-Operating | |||||
| Interest Income | 249.4M | 149.5M | 286.4M | 11.3M | 2.7M |
| Interest Expense | 4.0B | 4.2B | 5.3B | 2.9B | 736.6M |
| Net Interest Income | (3.7B) | (4.0B) | (5.0B) | (2.9B) | (733.9M) |
| Other Non-Op Income/Expense | (3.5B) | (3.6B) | (5.8B) | (7.0B) | (15.4B) |
| Non-Operating Income (excl Interest) | 447.5M | — | 563.7M | 4.2B | 14.7B |
| EBT (Pre-Tax Income) | (7.8B) | (212.0M) | 2.9B | (3.9B) | (22.8B) |
| Income Tax Expense | (1.6B) | 15.7M | 1.7B | (42.4M) | (851.7M) |
| Bottom Line | |||||
| Net Income | (6.3B) | (227.7M) | 1.2B | (3.9B) | (22.0B) |
| Earnings from Cont. Ops | (6.3B) | (227.7M) | 1.2B | (3.9B) | (22.0B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (6.3B) | (227.7M) | 1.2B | (3.9B) | (22.0B) |
| Per Share | |||||
| Basic EPS | (₩34) | (₩1) | ₩7 | (₩21) | (₩120) |
| Diluted EPS | (₩34) | (₩1) | ₩7 | (₩21) | (₩120) |
| Revenue Per Share | ₩1,383 | ₩1,307 | ₩1,378 | ₩1,284 | ₩1,194 |
| Shares | |||||
| Basic Shares Outstanding | 182.9M | 194.5M | 182.9M | 182.9M | 182.9M |
| Diluted Shares Outstanding | 182.9M | 194.5M | 182.9M | 182.9M | 182.9M |
| Profitability Metrics | |||||
| EBITDA | 4.5B | 12.2B | 16.9B | 7.6B | (14.3B) |
| D&A | 9.1B | 8.8B | 8.7B | 8.7B | 7.8B |
| EBIT | (4.6B) | 3.4B | 8.2B | (1.0B) | (22.1B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026